VERA Form 4: Officer sold 15,000 shares, exercised 10,000 options

Vera Therapeutics (VERA) reported insider activity by its SVP, Finance and Chief Accounting Officer on a Form 4.

Rhea-AI Filing Summary

Vera Therapeutics (VERA) reported insider activity by its SVP, Finance and Chief Accounting Officer on a Form 4. The filing shows a sale of 15,000 Class A common shares on 11/11/2025 at a weighted-average price of $29.0583. The sale occurred across multiple trades between $29.03 and $29.17.

On 11/13/2025, the officer exercised 10,000 stock options at an exercise price of $3.9396, acquiring 10,000 Class A common shares. Following these transactions, the officer directly beneficially owned 57,839 shares. A related option grant covering the 10,000 shares vests with 1/4 on March 9, 2022 and 1/48 monthly thereafter. The share total includes 893 shares acquired under the company’s 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Young Joseph R

Role SVP, FINANCE, CHIEF ACCT OFFCR

Sold 15,000 shs ($436K)

Approx. gross sale proceeds $436K

Approx. exercise cost $39K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	$0.00
Exercise	Class A Common Stock	10,000	$3.9396	$39K
Sale	Class A Common Stock	15,000	$29.0583	$436K

Holdings After Transaction: Stock Option (right to buy) — 48,589 contracts (Direct); Class A Common Stock — 57,839 shares (Direct)

Footnotes (3)

1. F1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
2. F2. Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.
3. F3. 1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VERA report on this Form 4?

Sale of 15,000 shares on 11/11/2025 at a weighted-average $29.0583, and exercise of 10,000 stock options on 11/13/2025 at $3.9396.

How many VERA shares does the reporting officer own after these trades?

The officer directly beneficially owned 57,839 Class A common shares after the reported transactions.

At what prices were the VERA shares sold?

Sales were executed between $29.03 and $29.17, with a weighted-average price of $29.0583.

What were the terms of the exercised VERA stock options?

Options for 10,000 shares had an exercise price of $3.9396; vesting was 1/4 on March 9, 2022 and 1/48 monthly thereafter.

Does the reported share count include ESPP purchases?

Yes. The reported holdings include 893 shares acquired under the 2021 Employee Stock Purchase Plan.

What is a weighted-average sale price in this context?

It reflects multiple trades at prices from $29.03 to $29.17 averaged to $29.0583; detailed breakdowns are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 08:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Joseph R

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE, CHIEF ACCT OFFCR

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/11/2025		S		15,000	D	$29.0583(1)	47,839(2)	D
Class A Common Stock	11/13/2025		M		10,000	A	$3.9396	57,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.9396	11/13/2025		M			10,000	(3)	04/13/2031	Class A Common Stock	10,000	$0	48,589	D

Explanation of Responses:

1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

2. Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.

3. 1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

	/s/ Joseph R. Young	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.